Drug Type AAV based gene therapy |
Synonyms AAV2-GDNF gene therapy (Asklepios BioPharmaceutical), AAV2-GDNF-MSA, AAV2-GDNF-PD + [5] |
Target- |
Mechanism- |
Active Indication |
Inactive Indication- |
Originator Organization |
Active Organization |
Inactive Organization- |
Drug Highest PhasePhase 2 |
First Approval Date- |
Regulation- |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Parkinson Disease | Phase 2 | US | 11 Jun 2024 | |
Multiple System Atrophy | Phase 1 | US | 30 Nov 2022 |
Phase 1 | 11 | pazaungffp(uckyebgwho) = The study met its primary objective, no attributed serious adverse events in all 11 patients at 18 months cqgsynswsm (kmyyybrwiu ) Met | Positive | 04 Jan 2024 | |||
Phase 1 | 10 | iyljfunuee(slgfgvjomj) = No AAV2-GDNF associated SAEs have been reported ueftefwdym (gxuhxfdrmf ) View more | Positive | 02 May 2022 | |||
Placebo |